Phase Ii Study Of Low-Dose Cyclophosphamide And Ipilimumab In Metastatic Melanoma.
JOURNAL OF CLINICAL ONCOLOGY(2014)
摘要
e20025 Background: Ipilimumab (Ipi) has improved clinical outcomes in metastatic melanoma (MM). Previous data suggested that low doses of cyclophosphamide (ldCTX) may have immunomodulatory effects ...
更多查看译文
关键词
metastatic melanoma,ipilimumab,low-dose
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要